PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Norethisterone Enantate→

Norethisterone Enantate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
3836-23-5
Molecular formula
C27H38O3
Molecular weight
410.6 g/mol
Drug class
Long-acting progestogen esterinjectable norethisterone prodrug
Mechanism of action
After intramuscular administration, norethisterone enantate is slowly released and hydrolysed to norethisterone, which activates progesterone receptors and suppresses ovulation, thickens cervical mucus and alters the endometrium.
Indications / reported uses
  • Long-acting progestogen-only contraception by intramuscular injection in countries where norethisterone enantate products are authorised; it is not the same as oral norethisterone indications for endometriosis or abnormal uterine bleeding

Sources: WHO — Family planning and injectable progestogens · PubMed — Norethisterone enantate contraceptive pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Norethisterone Enantate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Norethisterone Enantate Permitted Daily Exposure (PDE) report (the Norethisterone Enantate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Norethisterone Enantate Occupational Exposure Limit (OEL) report (the Norethisterone Enantate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.